Compare Stocks: SEPN, RYTM, CGON, and MIRM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$72.35	$73.79	$32.57 ▼ $80.97	$6.41B	0.24	639,213 shs	759,833 shs
MIRM Mirum Pharmaceuticals	$98.22	$106.81	$63.23 ▼ $130.00	$6.38B	0.49	455,605 shs	441,099 shs
RYTM Rhythm Pharmaceuticals	$104.71	$108.65	$74.50 ▼ $122.20	$7.18B	1.97	438,820 shs	573,720 shs
SEPN Septerna	$38.51	$37.79	$14.00 ▼ $51.10	$1.80B	2.3	320,362 shs	354,296 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	-3.11%	-3.57%	+21.49%	+117.01%
MIRM Mirum Pharmaceuticals	0.00%	-2.66%	-2.40%	-2.75%	+32.18%
RYTM Rhythm Pharmaceuticals	0.00%	+1.92%	-9.33%	+16.73%	+8.82%
SEPN Septerna	0.00%	+4.79%	-13.46%	+6.88%	+169.68%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$72.35	$73.79	$32.57 ▼ $80.97	$6.41B	0.24	639,213 shs	759,833 shs
MIRM Mirum Pharmaceuticals	$98.22	$106.81	$63.23 ▼ $130.00	$6.38B	0.49	455,605 shs	441,099 shs
RYTM Rhythm Pharmaceuticals	$104.71	$108.65	$74.50 ▼ $122.20	$7.18B	1.97	438,820 shs	573,720 shs
SEPN Septerna	$38.51	$37.79	$14.00 ▼ $51.10	$1.80B	2.3	320,362 shs	354,296 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	-3.11%	-3.57%	+21.49%	+117.01%
MIRM Mirum Pharmaceuticals	0.00%	-2.66%	-2.40%	-2.75%	+32.18%
RYTM Rhythm Pharmaceuticals	0.00%	+1.92%	-9.33%	+16.73%	+8.82%
SEPN Septerna	0.00%	+4.79%	-13.46%	+6.88%	+169.68%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.73	Moderate Buy	$87.78	21.32% Upside
MIRM Mirum Pharmaceuticals	2.93	Moderate Buy	$137.31	39.80% Upside
RYTM Rhythm Pharmaceuticals	2.74	Moderate Buy	$141.12	34.77% Upside
SEPN Septerna	2.82	Moderate Buy	$52.44	36.18% Upside

Current Analyst Ratings Breakdown

Latest SEPN, RYTM, CGON, and MIRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2026	RYTM Rhythm Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
8/27/2026	MIRM Mirum Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$137.00
8/27/2026	MIRM Mirum Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/27/2026	MIRM Mirum Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$137.00
8/19/2026	SEPN Septerna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$38.00 ➝ $48.00
8/13/2026	SEPN Septerna	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$43.00 ➝ $62.00
8/12/2026	SEPN Septerna	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $50.00
8/12/2026	SEPN Septerna	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $60.00
8/11/2026	SEPN Septerna	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$49.00
8/11/2026	SEPN Septerna	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$49.00
8/11/2026	SEPN Septerna	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $51.00

(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$4.04M	1,587.40	N/A	N/A	$9.33 per share	7.75
MIRM Mirum Pharmaceuticals	$521.31M	12.23	$0.05 per share	1,926.67	$6.12 per share	16.05
RYTM Rhythm Pharmaceuticals	$189.76M	37.82	N/A	N/A	$2.08 per share	50.34
SEPN Septerna	$45.95M	39.12	N/A	N/A	$8.53 per share	4.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
MIRM Mirum Pharmaceuticals	-$23.36M	-$14.55	N/A	N/A	N/A	-139.18%	-36.28%	-8.54%	11/3/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)
SEPN Septerna	-$48.88M	-$0.54	N/A	N/A	N/A	-24.51%	-9.57%	-6.28%	11/9/2026 (Estimated)

Latest SEPN, RYTM, CGON, and MIRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	SEPN Septerna	-$0.4260	-$0.29	+$0.1360	-$0.29	$19.22 million	$26.75 million
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/5/2026	Q2 2026	MIRM Mirum Pharmaceuticals	-$0.7425	-$1.06	-$0.3175	-$1.06	$166.33 million	$176.24 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SEPN Septerna	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
MIRM Mirum Pharmaceuticals	1.28	2.86	2.74
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20
SEPN Septerna	N/A	4.99	4.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
MIRM Mirum Pharmaceuticals	N/A
RYTM Rhythm Pharmaceuticals	N/A
SEPN Septerna	N/A

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
MIRM Mirum Pharmaceuticals	8.32%
RYTM Rhythm Pharmaceuticals	5.90%
SEPN Septerna	5.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
MIRM Mirum Pharmaceuticals	433	64.93 million	59.53 million	Optionable
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable
SEPN Septerna	130	46.68 million	43.97 million	N/A

SEPN, RYTM, CGON, and MIRM Headlines

Recent News About These Companies

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 10, 2026 | globenewswire.com

First Light Asset Management LLC Increases Stake in Septerna, Inc. $SEPN

September 10, 2026 | marketbeat.com

Septerna (NASDAQ:SEPN) Trading 4.8% Higher - Still a Buy?

September 9, 2026 | marketbeat.com

Bank of New York Mellon Corp Acquires New Position in Septerna, Inc. $SEPN

September 9, 2026 | marketbeat.com

Septerna (NASDAQ:SEPN) SVP Daniel Long Sells 3,333 Shares of Stock

September 4, 2026 | insidertrades.com

Septerna (NASDAQ:SEPN) SVP Sells $126,087.39 in Stock

September 3, 2026 | marketbeat.com

Septerna to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

BlackRock Inc. Purchases Shares of 1,932,088 Septerna, Inc. $SEPN

August 31, 2026 | marketbeat.com

Jupiter Topco LLC Invests $43.72 Million in Septerna, Inc. $SEPN

August 28, 2026 | marketbeat.com

Primecap Management Co. CA Takes $39.10 Million Position in Septerna, Inc. $SEPN

August 27, 2026 | marketbeat.com

Elmind Capital LP Purchases New Holdings in Septerna, Inc. $SEPN

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Buys New Stake in Septerna, Inc. $SEPN

August 26, 2026 | marketbeat.com

Algert Global LLC Grows Stake in Septerna, Inc. $SEPN

August 26, 2026 | marketbeat.com

Septerna names Rajiv Patni as CMO

August 25, 2026 | msn.com

Septerna Appoints Rajiv Patni as Chief Medical Officer

August 25, 2026 | tipranks.com

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

August 25, 2026 | globenewswire.com

Septerna, Inc. (NASDAQ:SEPN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 22, 2026 | marketbeat.com

Septerna (NASDAQ:SEPN) Stock Price Down 8% - Time to Sell?

August 20, 2026 | marketbeat.com

Septerna (NASDAQ:SEPN) Price Target Raised to $48.00

August 19, 2026 | marketbeat.com

4,211,659 Shares in Septerna, Inc. $SEPN Acquired by Trv Gp Vi LLC

August 19, 2026 | marketbeat.com

Trv Gp V LLC Takes Position in Septerna, Inc. $SEPN

August 19, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN, RYTM, CGON, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

$72.35 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$71.81 -0.54 (-0.75%)

As of 07:58 AM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$98.22 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$97.88 -0.34 (-0.35%)

As of 08:56 AM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$104.71 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$103.50 -1.21 (-1.16%)

As of 08:54 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Septerna NASDAQ:SEPN

$38.51 0.00 (0.00%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$38.51 0.00 (0.00%)

As of 07:07 AM Eastern

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body. Due to their significant role in human diseases, GPCRs have been the most productive target class in drug discovery history, accounting for approximately one-third of all U.S. Food and Drug Administration (FDA) approved drugs, representing approximately 500 products with combined global revenue of approximately $125 billion in 2023. Despite the pharmacological and commercial success of GPCR-targeted agents, about 75% of potential GPCR therapeutic targets remain undrugged and, for certain validated GPCRs, novel binding pockets may exist that could offer enhanced therapeutic benefits. Each step in GPCR activation involves subtle conformational changes that have been historically challenging to reproduce outside of a cell. The inability to isolate GPCR proteins in their native functional form outside of a cellular context has prevented scientists from leveraging some of the state-of-the-art technologies that have revolutionized drug discovery in other major target classes over the past decade. This complex challenge has limited GPCR drug discovery, particularly the development of novel oral small molecules, such as agonists (which activate GPCR signaling) for peptide GPCRs and allosteric modulators (which either increase or decrease the degree of GPCR activation by endogenous ligands). Our proprietary Native Complex Platform™ replicates the natural structure, function, and dynamics of GPCRs outside of cells at an industrial scale for, as we believe it, the first time. Our foundational technologies enable us to isolate, purify, and reconstitute full-length, properly folded GPCR proteins within ternary complexes with ligands and transducer proteins in a lipid bilayer that mimics the cell membrane. We then apply state-of-the-art discovery tools and technologies to these defined and tunable protein complexes to structurally design, screen for, and optimize potential product candidates. Leveraging our platform, we conduct GPCR oral small molecule drug discovery using an industrialized and iterative structure-based drug design approach for a diverse collection of GPCR targets. Our Native Complex PlatformTM is designed to enable us to target specific GPCRs, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists (which inhibit GPCR signaling), and allosteric modulators, to affect GPCR signaling in different ways to achieve desired therapeutic effects. We are advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. Our wholly-owned pipeline, is focused initially on three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. We intend to evaluate opportunities in other major therapeutic areas, such as neurology, women's health, cardiovascular, and respiratory disease. --- Leveraging our team, scientific and technical advisors, and our proprietary Native Complex Platform™, we aim to be a leader in the development of oral GPCR-targeted medicines for patients with significant unmet needs. We were incorporated under the laws of the State of Delaware in December 2019 under the name GPCR NewCo, Inc. and changed our name to Septerna, Inc. in June 2021. Our principal executive offices are located at 250 East Grand Avenue, South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SEPN, RYTM, CGON, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SEPN, RYTM, CGON, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SEPN, RYTM, CGON, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN, RYTM, CGON, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

Mirum Pharmaceuticals NASDAQ:MIRM

Rhythm Pharmaceuticals NASDAQ:RYTM

Septerna NASDAQ:SEPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SEPN, RYTM, CGON, and MIRM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SEPN, RYTM, CGON, and MIRM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SEPN, RYTM, CGON, and MIRM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SEPN, RYTM, CGON, and MIRM Company Descriptions

CG Oncology NASDAQ:CGON

Mirum Pharmaceuticals NASDAQ:MIRM

Rhythm Pharmaceuticals NASDAQ:RYTM

Septerna NASDAQ:SEPN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools